Pharmaceutical Resources News

Par Pharmaceutical Companies, Inc. today announced the results of its "Modified Dutch Auction" tender offer, in which Par offered to purchase, for cash, up to $65,000,000 aggregate principal amount, or up to approximately 82.7%, of its outstanding 2.875% Senior Subordinated Convertible Notes due 2010.

Par Pharmaceutical Companies, Inc. today announced that it has received final approval from the FDA for its Abbreviated New Drug Application for the 100mg and 200mg strengths of tramadol ER.

Generic drugmaker Par Pharmaceutical Companies Inc. said Friday its profit surged in the third quarter on a boost in product sales.

BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released Friday, November 6th and determining how the stocks have performed after their last 12 quarterly, 6 quarterly and November earnings reports.

Clinical Data, Inc . today announced the election of Scott Tarriff to the Board of Directors.

Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc.

Protox Therapeutics Inc. , a leader in the development of receptor targeted fusion proteins, today announced positive 12 month data from its open-label Phase 2 study of PRX302 in males with moderate to severe benign prostatic hyperplasia .

Protox Therapeutics Inc. , a leader in the development of receptor targeted fusion proteins, today announced that Dr.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc.

Par Pharmaceutical Companies, Inc. today announced that its licensing partner, Aveva Drug Delivery Systems, has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for a clonidine transdermal system.

Par Pharmaceutical Companies, Inc. today announced that the U.S. District Court for the District of Delaware has ruled in favor of Par in its challenge of Purdue's patents relating to extended-release tramadol, which are listed in the Orange Book for Ortho-McNeil's UltramA ER product.

Biopharmaceutical company Protox Therapeutics Inc. reported a net loss Friday of $1.8 million or two cents a share for the quarter ended June 30, compared with $1.9 million or three cents for the comparable 2008 quarter.

WOODCLIFF LAKE, N.J., June 12 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc.

WOODCLIFF LAKE, N.J., June 16 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc.

Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc., has announced that the FDA has accepted its New Drug Application for ondansetron orally dissolving film strip .

Bothell, WA-based MDRNA said today that a generic calcitonin nasal spray for osteoporosis has received FDA approval, and has been introduced to the market.

Jun 11, 2009 - SOHM Inc. has been rated Speculative Buy with a price target of $0.33 by Beacon Analyst, Victor Sula, Ph.D. The full report is available at http://www.beaconequity.com . Anyone interested in receiving alerts regarding SHMN research should e-mail members@beaconequity.com with "SHMN" in the subject line.

Main Category: Cancer / Oncology Also Included In: Regulatory Affairs / Drug Approvals ; Pharma Industry / Biotech Industry Article Date: 11 Jun 2009 - 5:00 PDT MonoSol Rx, the developers of PharmFilm technology and a drug delivery company specializing in dissolving thin film pharmaceutical products, announced that the new drug application for ...

Shares of the following companies made notable moves in the stock market Tuesday: Advancers MDRNA Inc.